PST-611 treatment for geographic atrophy
Part of Eyes & vision clinical trials.
This trial tests an investigational treatment called PST-611 for geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. It aims to see if the treatment is safe and may slow the progression of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 years of age or older.
- You have geographic atrophy in at least one eye, confirmed by a doctor.
- Your geographic atrophy has shown signs of growth in the past 3 to 12 months.
- Your vision in the study eye is 20/32 or worse.
- You have not had eye surgery or certain eye treatments in the past 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called STL303 for geographic atrophy, a condition where the back of the eye slowly loses cells, causing vision loss. The drug aims to slow or stop this vision loss in people over 60.
This trial tests a new nerve stimulation treatment for people with geographic atrophy, a form of advanced dry age-related macular degeneration. It aims to see if this treatment can help preserve or improve vision.
This study tests a single injection of an experimental drug (SAR446597) into the eye for people with geographic atrophy, a late-stage form of dry age-related macular degeneration. The goal is to see if it can safely slow vision loss.
This study tests an investigational medicine called ONL1204 given as an injection into the eye for people with a form of advanced dry age-related macular degeneration called geographic atrophy. The goal is to see if it can slow vision loss.
This study tests a new medicine (ABBV-6628) given as an injection into the eye to see how well it works and how it moves through the body for people with geographic atrophy (an advanced form of dry age-related macular degeneration). It may help slow vision loss from this condition.
This trial tests a new treatment called Eyecyte-RPE™, made from special cells that support the retina. It is given as a single injection under the retina during eye surgery. The study aims to see if it can help people with advanced dry age-related macular degeneration (AMD) who have large areas of damage (geographic atrophy) in the center of their vision.
Hear when a new Geographic Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.